Skip to main content
FULC
NASDAQ Life Sciences

10% Owner Kevin Tang Buys $891K of Fulcrum Stock After Pipeline Collapse

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$3.57
Mkt Cap
$237.215M
52W Low
$2.83
52W High
$15.74
52W Position info
26% above low
Off High info
77% below high
Rel. Volume info
0.4× avg
Market data snapshot near publication time

FULC sits 26% above its 52-week low of $2.83 on light trading volume (0.4× avg).

Summary

10% owner Kevin Tang bought $891K of Fulcrum stock in open-market purchases, a notable vote of confidence following the company's recent pipeline failure and restructuring.


Key Events · Ownership and Investor Activity · FULC

  • 10% Owner Buys $891K in Stock

    Kevin Tang, through affiliated entities, purchased 249,946 shares for $891,067 at prices between $3.50 and $3.60 from July 13-15, increasing his indirect holdings to 6,913,329 shares.

  • Post-Crisis Conviction Buy

    The purchase follows Fulcrum's June 1 discontinuation of its lead sickle cell drug and an 85% workforce reduction, suggesting Tang sees value in the remaining pipeline and cash runway.

  • No Prior Disclosure

    This Form 4 is the first public disclosure of these transactions; no earlier filings or news reported the purchases.


Analysis · FULC · Life Sciences

Kevin Tang, a 10% owner, spent $891,067 buying 249,946 shares on the open market over three days at prices near $3.56. This comes just six weeks after Fulcrum discontinued its lead sickle cell program and slashed 85% of its workforce. The purchase signals conviction from a large, informed investor that the remaining pipeline and cash runway justify the current valuation, even as the company navigates a strategic review.

How filings like this one have moved

In the 30 days to Sep 14, 2026, 29.9% of the 1591 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.24%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, FULC was trading at $3.57 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $237.2M. The 52-week trading range was $2.83 to $15.74. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

FULC - Latest Insights

FULC
Sep 01, 2026, 9:42 PM EDT
Filing Type: S-4
Importance Score:
9
Price at Filing: $3.80
Real-time Price: $3.80 info
Change: +$0.0045 (+0.12%) info
Market Cap: $289.93M info
FULC
Aug 17, 2026, 1:16 PM EDT
Source: Benzinga
Importance Score:
9
Price at Filing: $3.78
Real-time Price: $3.80 info
Change: +$0.020 (+0.53%) info
Market Cap: $289.93M info
FULC
Aug 17, 2026, 8:33 AM EDT
Filing Type: 425
Importance Score:
9
Price at Filing: $3.80
Real-time Price: $3.80 info
Change: $0 (0%) info
Market Cap: $289.93M info
FULC
Aug 17, 2026, 8:31 AM EDT
Filing Type: 425
Importance Score:
9
Price at Filing: $3.80
Real-time Price: $3.80 info
Change: $0 (0%) info
Market Cap: $289.93M info
FULC
Aug 17, 2026, 8:30 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $3.80
Real-time Price: $3.80 info
Change: +$0.0005 (+0.01%) info
Market Cap: $289.93M info